JP2021529524A5 - - Google Patents

Info

Publication number
JP2021529524A5
JP2021529524A5 JP2020573044A JP2020573044A JP2021529524A5 JP 2021529524 A5 JP2021529524 A5 JP 2021529524A5 JP 2020573044 A JP2020573044 A JP 2020573044A JP 2020573044 A JP2020573044 A JP 2020573044A JP 2021529524 A5 JP2021529524 A5 JP 2021529524A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding fragment
glyco
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573044A
Other languages
English (en)
Japanese (ja)
Other versions
JP7541930B2 (ja
JP2021529524A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039883 external-priority patent/WO2020006449A1/en
Publication of JP2021529524A publication Critical patent/JP2021529524A/ja
Publication of JP2021529524A5 publication Critical patent/JP2021529524A5/ja
Application granted granted Critical
Publication of JP7541930B2 publication Critical patent/JP7541930B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573044A 2018-06-29 2019-06-28 抗グリコmuc1抗体およびその使用 Active JP7541930B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862691887P 2018-06-29 2018-06-29
US62/691,887 2018-06-29
US201962802865P 2019-02-08 2019-02-08
US62/802,865 2019-02-08
PCT/US2019/039883 WO2020006449A1 (en) 2018-06-29 2019-06-28 Anti-glyc0-muc1 antibodies and their uses

Publications (3)

Publication Number Publication Date
JP2021529524A JP2021529524A (ja) 2021-11-04
JP2021529524A5 true JP2021529524A5 (cg-RX-API-DMAC7.html) 2022-07-06
JP7541930B2 JP7541930B2 (ja) 2024-08-29

Family

ID=68987626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573044A Active JP7541930B2 (ja) 2018-06-29 2019-06-28 抗グリコmuc1抗体およびその使用

Country Status (5)

Country Link
US (2) US12269892B2 (cg-RX-API-DMAC7.html)
EP (1) EP3814384A4 (cg-RX-API-DMAC7.html)
JP (1) JP7541930B2 (cg-RX-API-DMAC7.html)
CN (1) CN112996816B (cg-RX-API-DMAC7.html)
WO (1) WO2020006449A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7859981B2 (ja) * 2020-03-06 2026-05-15 ジーオー セラピューティクス,インコーポレイテッド 抗グリコcd44抗体およびその使用
CN116322770A (zh) * 2020-07-31 2023-06-23 R·P·舍勒科技有限责任公司 对粘蛋白-1特异的抗体及其使用方法
WO2023121448A1 (en) * 2021-12-21 2023-06-29 Merus N.V. Binding domains against cancer-associated muc1
WO2025114381A1 (en) * 2023-11-27 2025-06-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Muc1 antibodies and uses thereof
WO2026132383A2 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag ANTIBODIES BINDING TO Tn-MUC-1
WO2026132145A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Antibodies binding to tn-muc-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008711A1 (en) 1988-03-11 1989-09-21 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001075110A2 (en) 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
US7338932B2 (en) 2000-05-11 2008-03-04 Glycozym Aps Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1141142C (zh) * 2001-02-08 2004-03-10 北京迪威华宇生物技术有限公司 人乳腺癌muc-1抗原基因工程疫苗
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
JP2010505775A (ja) * 2006-10-04 2010-02-25 クーベンハヴンス・ユニヴェルシテット Muc1に対する癌特異的な免疫反応の産生及び癌特異的muc1抗体
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
KR101534881B1 (ko) * 2007-07-31 2015-07-07 가부시키가이샤 도우사 고가쿠 겐큐쇼 펩티드의 제조방법
CA2707689A1 (en) 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2741798A1 (en) 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US9588121B2 (en) * 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン1(muc1)タンパク質に対する抗体及びその用途
WO2011135869A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なmuc1抗体
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015120180A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
JP6476170B2 (ja) * 2014-04-28 2019-03-06 医化学創薬株式会社 抗muc1抗体又はその抗原結合性断片及びその用途
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
CN108290958B (zh) 2015-10-02 2021-12-28 豪夫迈·罗氏有限公司 多特异性抗体
EP3601357A1 (en) 2017-03-29 2020-02-05 Glycotope GmbH Multispecific antibody constructs binding to muc1 and cd3

Similar Documents

Publication Publication Date Title
JP7562528B2 (ja) 抗体及びその用途
JP2022512132A5 (cg-RX-API-DMAC7.html)
JP7620807B2 (ja) 抗SIRPα抗体およびその適用
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP2020073504A5 (cg-RX-API-DMAC7.html)
JP2019116474A5 (cg-RX-API-DMAC7.html)
JP2021510710A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
KR20210100654A (ko) Cd3 항체 및 그의 약제학적 용도
JP2019527553A5 (cg-RX-API-DMAC7.html)
JP2020508655A5 (cg-RX-API-DMAC7.html)
KR20180012860A (ko) 이종 이량체 다중 특이적 항체 포맷
JP2018522888A5 (cg-RX-API-DMAC7.html)
AU2019242559A1 (en) Monoclonal antibodies that bind to SSEA4 and uses thereof
CN113150156B (zh) 抗tigit抗体及其用途
JP2021512604A5 (cg-RX-API-DMAC7.html)
JP2024515560A5 (cg-RX-API-DMAC7.html)
WO2023071676A1 (zh) 一种抗her2/抗pd-l1双功能抗体及其应用
CA3229160A1 (en) Bispecific tetravalent antibody targeting egfr and her3
CN119213023A (zh) Ilt3和cd3结合剂以及其使用方法
US12577314B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
JP2024543828A5 (cg-RX-API-DMAC7.html)
JP2024531915A5 (cg-RX-API-DMAC7.html)
KR20250012612A (ko) 고형 종양을 치료하는 방법
JP2024512324A5 (cg-RX-API-DMAC7.html)